Suicide-Gene-Transduced Donor T-Cells for Controlled Graft-versus-Host Disease and Graft-Versus-Tumor

Progress in hematology
  • 46 Downloads

Abstract

In allogeneic hematopoietic cell transplantation, donor lymphocytes play a central therapeutic role in both graft-versus-leukemia and immune reconstitution. However, their use is limited by the risk of severe graft-versus-host disease (GVHD). Different strategies have been investigated to obtain all the benefits derived from donor lymphocytes while avoiding the risk of GVHD. Infusions of donor lymphocytes transduced with the herpes simplex virus thymidine kinase (HSV-tk) suicide gene resulted in anti-tumor activity in a substantial number of patients.Acute GVHD could be effectively controlled by ganciclovir-induced elimination of the transduced cells. Haplo-identical stem cell transplantation (haplo-SCT) is a promising therapeutic option for patients with high-risk hematologic malignancies lacking an HLA-matched donor. However, the intensive T-cell depletion required to overcome the risk of lethal GVHD has been associated with a delayed immune recovery with a prolonged risk of posttransplantation viral, fungal, and other opportunistic infections. Donor lymphocyte infusions of HSV-tk represent a promising tool for preventing disease relapse and promoting immune reconstitution after haplo-SCT, and a unique tool for the control of GVHD. The genetic manipulation of donor lymphocytes with a suicide gene is a promising strategy to increase feasibility and safety of allogeneic bone marrow transplantation. Int J Hematol. 2002;76:305-309.

Key words

Hematopoietic cell transplantation Gene therapy Suicide gene Graft-versus-tumor 

References

  1. 1.
    Ringden O, Horowitz MM, Gale RP, et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults.JAMA. 1993;270:57–60.PubMedCrossRefGoogle Scholar
  2. 2.
    Armitage JO. Bone marrow transplantation.N Engl J Med. 1994; 330:827–838.PubMedCrossRefGoogle Scholar
  3. 3.
    Klingemann HG, Storb R, Fefer A, et al. Bone marrow transplantation in patients aged 45 years and older.Blood. 1986;67:770–776.PubMedGoogle Scholar
  4. 4.
    Appelbaum FR. Haematopoietic cell transplantation as immunotherapy.Nature. 2001;411:385–389.PubMedCrossRefGoogle Scholar
  5. 5.
    Basara N, Blau IW, Willenbacher W, Kiehl MG, Fauser AA. New strategies in the treatment of graft-versus-host disease.Bone Marrow Transplant. 2000;25:S12-S15.PubMedCrossRefGoogle Scholar
  6. 6.
    Gaziev D, Galimberti M, Lucarelli G, Polchi P. Chronic graft-ver-sus-host disease: is there an alternative to the conventional treatment?Bone Marrow Transplant. 2000;25:689–696.PubMedCrossRefGoogle Scholar
  7. 7.
    Barnes DWH, et al. Treatment of murine leukemia with x-rays and homologous bone marrow.BMJ. 1956;2:626–627.PubMedCrossRefGoogle Scholar
  8. 8.
    Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.N Engl J Med. 1979;300:1068–1073.PubMedGoogle Scholar
  9. 9.
    Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation.Blood. 1990;75: 555–562.PubMedGoogle Scholar
  10. 10.
    Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.Blood. 1990;76:2462–2465.PubMedGoogle Scholar
  11. 11.
    Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia.Blood. 1995;86: 2041–2050.PubMedGoogle Scholar
  12. 12.
    Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.Blood. 1995;86:1261–1268.PubMedGoogle Scholar
  13. 13.
    Collins RH, Jr., Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.J Clin Oncol. 1997;15:433–444.PubMedGoogle Scholar
  14. 14.
    Porter DL, Connors JM, Van Deerlin VM, et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies.J Clin Oncol. 1999;17:1234.PubMedGoogle Scholar
  15. 15.
    Collins RH, Jr., Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia.Bone Marrow Transplant. 2000;26:511–516.PubMedCrossRefGoogle Scholar
  16. 16.
    Schmid C, Lange C, Salat C, et al. Treatment of recurrent acute leukemia after marrow transplantation with donor cells and GM-CSF [abstract].Blood. 1999;94 (10 suppl 1):668a. Abstract 2965.Google Scholar
  17. 17.
    Porter DL, Collins RH, Jr., Shpilberg O, et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.Biol Blood Marrow Transplant. 1999;5:253–261.PubMedCrossRefGoogle Scholar
  18. 18.
    Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.Blood. 1997;90:4206–4211.PubMedGoogle Scholar
  19. 19.
    Mandigers CM, Meijerink JP, Raemaekers JM, Schattenberg AV, Mensink EJ. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real- time quantitative PCR analysis of t(14;18).Lancet. 1998;352:1522–1523.PubMedCrossRefGoogle Scholar
  20. 20.
    Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia.Blood. 2000;95:67–71.PubMedGoogle Scholar
  21. 21.
    Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.Blood. 1995;86: 4337–4343.PubMedGoogle Scholar
  22. 22.
    Falkenburg JH,Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.Blood. 1999;94: 1201–1208.PubMedGoogle Scholar
  23. 23.
    Bordignon C, Carlo-Stella C, Colombo MP, et al. Cell therapy: achievements and perspectives.Haematologica. 1999;84:1110–1149.PubMedGoogle Scholar
  24. 24.
    Bordignon C, Bonini C, Verzeletti S, et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation.Hum Gene Ther. 1995;6:813–819.PubMedCrossRefGoogle Scholar
  25. 25.
    Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.Science. 1997;276:1719–1724.PubMedCrossRefGoogle Scholar
  26. 26.
    Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients.Science. 1995;270:470–475.PubMedCrossRefGoogle Scholar
  27. 27.
    Bonini C, Ciceri F, Marktel S, Bordignon C. Suicide-gene-transduced T- cells for the regulation of the graft-versus-leukemia effect.Vox Sang. 1998;74:341–343.PubMedGoogle Scholar
  28. 28.
    Tiberghien P, Cahn JY, Brion A, et al. Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study.Hum Gene Ther. 1997;8:615–624.PubMedCrossRefGoogle Scholar
  29. 29.
    Tiberghien P, Ferrand C, Lioure B, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft.Blood. 2001;97:63–72.PubMedCrossRefGoogle Scholar
  30. 30.
    Champlin R, Besinger W, Henslee-Downey J, et al. Phase I/II study of thymidine kinase (TK)-transduced donor lymphocyte infusions (DLI) in patients with hematologic malignancies [abstract].Blood. 1999;94:1448a.Google Scholar
  31. 31.
    Verzeletti S, Bonini C, Marktel S, et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors.Hum Gene Ther. 1998;9:2243–2251.PubMedCrossRefGoogle Scholar
  32. 32.
    Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.N Engl J Med. 1998;339: 1186–1193.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  1. 1.Cancer Immune Therapy and Gene Therapy ProgramSan Raffaele Scientific InstituteMilanoItaly
  2. 2.Department of HematologyBone Marrow Transplantation UnitMilanoItaly

Personalised recommendations